Johnson & Johnson vs Eli Lilly
JNJ and LLY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JNJ and LLY compare
Eli Lilly is the larger company, worth 2.0 times as much as Johnson & Johnson ($1.3T against $658B).
On earnings, Johnson & Johnson is cheaper: it trades at 31.7× trailing earnings, against 46.0× for Eli Lilly.
Eli Lilly grew revenue faster over the last twelve months (45.5% versus 8.1% for Johnson & Johnson).
Eli Lilly keeps more of each dollar of sales as profit, with a net margin of 31.9% compared with 21.5% at Johnson & Johnson.
Both pay dividends: Johnson & Johnson yields 1.9% and Eli Lilly 0.47%.
Eli Lilly scores higher on the StockData Score (20 against 12 for Johnson & Johnson), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JNJ | LLY |
|---|---|---|
| Size and price | ||
| Market cap | $658B | $1.3T |
| Share price | $273.20 | $1417.54 |
| Change, 1 year | 46.4% | 74.2% |
| Change, 5 years | 67.2% | 435% |
| Beta (5Y) | 0.20 | 0.52 |
| Employees | 138K | 50K |
| StockData Score | ||
| Total score | 12 | 20 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 3 | 6 (better) |
| Performance score | 4 | 5 (better) |
| Health score | 3 | 4 (better) |
| Dividend score | 2 | 3 (better) |
| Valuation | ||
| P/E | 31.7× (better) | 46.0× |
| P/S | 6.7× (better) | 15.4× |
| P/B | 7.7× (better) | 33.1× |
| EV/EBITDA | 20.2× (better) | 37.3× |
| P/FCF | 29.6× | – |
| PEG | 1.77 | 0.93 (better) |
| FCF yield | 3.4% | – |
| Fair value | $190.51 | $1125.50 |
| Margin of safety | −43.4% | −25.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 8.1% | 45.5% (better) |
| Revenue growth, 5Y average | 2.7% | 21.6% (better) |
| Net income growth (TTM) | −7.2% | 49.8% (better) |
| EPS growth (TTM) | −7.8% | 50.7% (better) |
| EPS growth, 5Y average | 14.9% | 27.6% (better) |
| Profitability | ||
| Gross margin | 67.9% | 83.6% (better) |
| Net margin | 21.5% | 31.9% (better) |
| FCF margin | 22.7% | – |
| Return on equity | 25.7% | 86.1% (better) |
| Financial health | ||
| Debt / equity | 0.58 (better) | 1.23 |
| Net debt / EBITDA | 0.83 (better) | 1.21 |
| Current ratio | 1.09 | 1.39 (better) |
| Altman Z-score | 5.11 | 8.52 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 1.9% (better) | 0.47% |
| Payout ratio | – | 21.7% |
| Years of dividend growth | 16 (better) | 9 |
| Dividend growth, 5Y average | 5.2% | 15.2% (better) |
| Buyback yield | 1.2% (better) | 0.44% |
| Shareholder yield | 3.2% (better) | 0.91% |
| Ownership | ||
| Held by institutions | 74.7% | 83.7% |
| Held by insiders | 0.04% | 10.4% |
| Insider net buying, 12 months | −$150M (better) | −$2.3B |
| Superinvestors holding | 6 (better) | 3 |
| Short interest, % of float | 0.92% | 0.83% |
Go deeper
- JNJ stock overview
- JNJ income statement
- JNJ valuation and score
- LLY stock overview
- LLY income statement
- LLY valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.